259 related articles for article (PubMed ID: 21766440)
21. The potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: a descriptive study.
Meijer WM; Cornel MC; Dolk H; de Walle HE; Armstrong NC; de Jong-van den Berg LT;
Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):675-82. PubMed ID: 16761260
[TBL] [Abstract][Full Text] [Related]
22. Use of medication during pregnancy and risk of childhood leukemia (Canada).
Shaw AK; Infante-Rivard C; Morrison HI
Cancer Causes Control; 2004 Nov; 15(9):931-7. PubMed ID: 15577295
[TBL] [Abstract][Full Text] [Related]
23. Caution advised in interpretation of US FDA risk classification for dermatological medications during pregnancy.
Wong JW; Heller MM; Murase JE
Dermatol Online J; 2012 Oct; 18(10):15. PubMed ID: 23122022
[TBL] [Abstract][Full Text] [Related]
24. Teratogen update: evaluation of the reproductive and developmental risks of caffeine.
Christian MS; Brent RL
Teratology; 2001 Jul; 64(1):51-78. PubMed ID: 11410911
[TBL] [Abstract][Full Text] [Related]
25. An overview of over the counter drugs in pregnancy and lactation.
Das BP; Joshi M; Pant CR
Kathmandu Univ Med J (KUMJ); 2006; 4(4):545-51. PubMed ID: 18603972
[TBL] [Abstract][Full Text] [Related]
26. Obstetric toxicology: teratogens.
Levine M; O'Connor AD
Emerg Med Clin North Am; 2012 Nov; 30(4):977-90. PubMed ID: 23137407
[TBL] [Abstract][Full Text] [Related]
27. How do we know if an exposure is actually teratogenic in humans?
Friedman JM
Am J Med Genet C Semin Med Genet; 2011 Aug; 157C(3):170-4. PubMed ID: 21766430
[TBL] [Abstract][Full Text] [Related]
28. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks.
Nahum GG; Uhl K; Kennedy DL
Obstet Gynecol; 2006 May; 107(5):1120-38. PubMed ID: 16648419
[TBL] [Abstract][Full Text] [Related]
29. Patterns of pregnancy exposure to prescription FDA C, D and X drugs in a Canadian population.
Wen SW; Yang T; Krewski D; Yang Q; Nimrod C; Garner P; Fraser W; Olatunbosun O; Walker MC
J Perinatol; 2008 May; 28(5):324-9. PubMed ID: 18288118
[TBL] [Abstract][Full Text] [Related]
30. A review of the contribution of whole embryo culture to the determination of hazard and risk in teratogenicity testing.
Webster WS; Brown-Woodman PD; Ritchie HE
Int J Dev Biol; 1997 Apr; 41(2):329-35. PubMed ID: 9184342
[TBL] [Abstract][Full Text] [Related]
31. Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs.
Uhl K; Kennedy DL; Kweder SL
Drug Saf; 2002; 25(12):885-92. PubMed ID: 12241129
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
[TBL] [Abstract][Full Text] [Related]
33. The clinical content of preconception care: the use of medications and supplements among women of reproductive age.
Dunlop AL; Gardiner PM; Shellhaas CS; Menard MK; McDiarmid MA
Am J Obstet Gynecol; 2008 Dec; 199(6 Suppl 2):S367-72. PubMed ID: 19081432
[TBL] [Abstract][Full Text] [Related]
34. Drug labeling and risk perceptions of teratogenicity: a survey of pregnant Canadian women and their health professionals.
Pole M; Einarson A; Pairaudeau N; Einarson T; Koren G
J Clin Pharmacol; 2000 Jun; 40(6):573-7. PubMed ID: 10868307
[TBL] [Abstract][Full Text] [Related]
35. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006).
Daw JR; Mintzes B; Law MR; Hanley GE; Morgan SG
Clin Ther; 2012 Jan; 34(1):239-249.e2. PubMed ID: 22169049
[TBL] [Abstract][Full Text] [Related]
36. Prescribing in pregnancy and during breast feeding: using principles in clinical practice.
Henderson E; Mackillop L
Postgrad Med J; 2011 May; 87(1027):349-54. PubMed ID: 21273359
[TBL] [Abstract][Full Text] [Related]
37. Drugs during pregnancy: an issue of risk classification and information to prescribers.
Sannerstedt R; Lundborg P; Danielsson BR; Kihlström I; Alván G; Prame B; Ridley E
Drug Saf; 1996 Feb; 14(2):69-77. PubMed ID: 8852521
[TBL] [Abstract][Full Text] [Related]
38. FDA classification of drugs for teratogenic risk. Teratology Society Public Affairs Committee.
Teratology; 1994 Jun; 49(6):446-7. PubMed ID: 7747265
[TBL] [Abstract][Full Text] [Related]
39. Prescription of hazardous drugs during pregnancy.
Malm H; Martikainen J; Klaukka T; Neuvonen PJ
Drug Saf; 2004; 27(12):899-908. PubMed ID: 15366977
[TBL] [Abstract][Full Text] [Related]
40. [Malformations in the offspring of pregnant women with epilepsy. Presentation of an international registry of antiepileptic drugs and pregnancy (EURAP)].
Battino D; Mamoli D; Messina S; Perucca E; Tomson T
Rev Neurol; 2002 Mar 1-15; 34(5):476-80. PubMed ID: 12040519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
